文献速递冠心病血脂与心血管预防

急性冠脉综合征患者双联抗血小板治疗的降阶策略

De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
PubMed 文献 · J Am Coll Cardiol · 2021-07-15

该网络荟萃分析纳入15项随机对照试验共55798例急性冠脉综合征患者,比较不同双联抗血小板治疗策略的疗效与安全性。结果显示,降阶治疗(从强效P2Y12抑制剂转换为氯吡格雷或低剂量普拉格雷)可降低出血风险,且不增加缺血事件。降阶至氯吡格雷或低剂量普拉格雷之间无显著差异。

要点

  • 降阶治疗较氯吡格雷、替格瑞洛、标准剂量及低剂量普拉格雷均降低出血风险。
  • 降阶治疗不增加心血管死亡、心肌梗死或卒中的复合终点风险。
  • 降阶至氯吡格雷与低剂量普拉格雷在缺血和出血结局上无显著差异。

核心结论

  • 在急性冠脉综合征患者中,降阶双联抗血小板治疗是减少出血事件且不增加缺血事件的有效策略。

研究设计与样本

  • 网络荟萃分析,检索MEDLINE和EMBASE至2021年1月,纳入15项随机对照试验,共55798例急性冠脉综合征患者。

主要发现

  • 降阶治疗与氯吡格雷相比,主要出血结局风险比为0.48(95%CI 0.30-0.77)。
  • 降阶治疗与替格瑞洛相比,主要出血结局风险比为0.32(95%CI 0.20-0.52)。
  • 降阶治疗与标准剂量普拉格雷相比,主要出血结局风险比为0.36(95%CI 0.24-0.55)。
  • 降阶治疗与低剂量普拉格雷相比,主要出血结局风险比为0.40(95%CI 0.22-0.75)。
  • 降阶治疗未对主要疗效结局产生负面影响,且降阶至氯吡格雷或低剂量普拉格雷之间无显著差异。

关键数值与推荐

  • 主要疗效结局为心血管死亡、心肌梗死和卒中的复合终点。
  • 主要出血结局为试验定义的大出血或小出血。

临床怎么用

  • 对于急性冠脉综合征患者,可考虑采用降阶双联抗血小板治疗策略以降低出血风险,尤其适用于出血风险较高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) management. Recent randomized controlled trials (RCTs) have investigated DAPT de-escalation to decrease the risk of bleeding outcomes. OBJECTIVES: The aim of this study was to compare the efficacy and safety outcomes of various DAPT strategies in patients with ACS, including de-escalation from a potent P2Y12 inhibitor to clopidogrel or low-dose prasugrel. METHODS: MEDLINE and EMBASE were searched through January 2021 for RCTs investigating the efficacy and safety of DAPT in patients with ACS, and a network meta-analysis was conducted. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, and stroke. The primary bleeding outcome was trial-defined major or minor bleeding. RESULTS: Our search identified 15 eligible RCTs, including 55,798 patients with ACS. De-escalation therapy was associated with reduced risk of primary bleeding outcomes (HR: 0.48 [95% CI: 0.30-0.77] vs clopidogrel; HR: 0.32 [95% CI: 0.20-0.52] vs ticagrelor; HR: 0.36 [95% CI: 0.24-0.55] vs standard-dose prasugrel; and HR: 0.40 [95% CI: 0.22-0.75] vs low-dose prasugrel) without negatively affecting primary efficacy outcomes. There were no significant differences in ischemic or bleeding outcomes between de-escalation to clopidogrel or low-dose prasugrel. CONCLUSIONS: Compared with other established uses of DAPT, de-escalation was the most effective strategy for ACS treatment, resulting in fewer bleeding events without increasing ischemic events.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Shoji S, Kuno T, Fujisaki T, et al. De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2021. PMID: 34275697. doi:10.1016/j.jacc.2021.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。